Literature DB >> 11053081

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

N Nishimoto1, T Kishimoto, K Yoshizaki.   

Abstract

Interleukin 6 (IL6) is a pleiotropic cytokine with a wide range of biological activities. IL6 transgene into mice gives rise to the abnormalities such as hypergammaglobulinaemia, thrombocytosis, infiltration of inflammatory cells into the tissues, mesangial cell proliferation of the kidney as well as splenomegaly and lymphadenopathy, which are predictable by the biological functions of IL6 shown in vitro. Continuous overproduction of IL6 is observed in patients with some immune-inflammatory diseases such as Castleman's disease and rheumatoid arthritis that are frequently associated with similar abnormalities to those of IL6 transgenic mice, strongly suggesting the involvement of IL6 in the human diseases. Successful treatment of the model animals for immune-inflammatory diseases with anti-IL6 receptor (IL6R) antibody thus indicates the possible application of IL6 blocking agents to treat the IL6 related immune-inflammatory diseases of humans. In this review, the new therapeutic strategy for Castleman's disease and RA using humanized antibody to human IL6 receptor, MRA, is discussed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11053081      PMCID： PMC1766618          DOI： 10.1136/ard.59.suppl_1.i21

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  65 in total

1.  Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines.

Authors:  T Noma; T Mizuta; A Rosén; T Hirano; T Kishimoto; T Honjo
Journal:  Immunol Lett       Date:  1987-07       Impact factor: 3.685

Review 2.  Differentiation and proliferation of hematopoietic stem cells.

Authors:  M Ogawa
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

3.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

4.  Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice.

Authors:  M Sasai; Y Saeki; S Ohshima; K Nishioka; T Mima; T Tanaka; Y Katada; K Yoshizaki; M Suemura; T Kishimoto
Journal:  Arthritis Rheum       Date:  1999-08

5.  Interleukin 6 and expression of its receptor on epidermal keratinocytes.

Authors:  K Yoshizaki; N Nishimoto; K Matsumoto; H Tagoh; T Taga; Y Deguchi; T Kuritani; T Hirano; K Hashimoto; N Okada
Journal:  Cytokine       Date:  1990-09       Impact factor: 3.861

6.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors:  R Madhok; A Crilly; J Watson; H A Capell
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

7.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

9.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

10.  Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha.

Authors:  A G Leary; K Ikebuchi; Y Hirai; G G Wong; Y C Yang; S C Clark; M Ogawa
Journal:  Blood       Date:  1988-06       Impact factor: 22.113
View more
  51 in total

1.  Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.

Authors:  J N Varghese; R L Moritz; M-Z Lou; A Van Donkelaar; H Ji; N Ivancic; K M Branson; N E Hall; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger.

Authors:  Tamotsu Kamishima; Kazuhide Tanimura; Masato Shimizu; Megumi Matsuhashi; Jun Fukae; Yujiro Kon; Hiromi Hagiwara; Akihiro Narita; Yuko Aoki; Naoki Kosaka; Tatsuya Atsumi; Hiroki Shirato; Satoshi Terae
Journal:  Skeletal Radiol       Date:  2010-11-14       Impact factor: 2.199

Review 3.  The role of immune tolerance in preventing and treating arthritis.

Authors:  Gijs Teklenburg; Salvatore Albani
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

4.  Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.

Authors:  Tadashi Okano; Kentaro Inui; Masahiro Tada; Yuko Sugioka; Kenji Mamoto; Shigeyuki Wakitani; Tatsuya Koike; Hiroaki Nakamura
Journal:  Rheumatol Int       Date:  2015-10-05       Impact factor: 2.631

5.  Synovial macrophage-osteoclast differentiation in inflammatory arthritis.

Authors:  L Danks; A Sabokbar; R Gundle; N A Athanasou
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

6.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

Review 7.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

8.  Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.

Authors:  Xiao Chen; Rupali Das; Richard Komorowski; Amy Beres; Martin J Hessner; Masahiko Mihara; William R Drobyski
Journal:  Blood       Date:  2009-06-02       Impact factor: 22.113

Review 9.  Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan.

Authors:  Masaaki Mori; Takuya Naruto; Tomoyuki Imagawa; Takuji Murata; Syuji Takei; Minako Tomiita; Yasuhiko Itoh; Satoshi Fujikawa; Shumpei Yokota
Journal:  Mod Rheumatol       Date:  2008-09-25       Impact factor: 3.023

10.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.